Inflammation 2005 - Seventh World Congress. Highlights I.
Enefer
Sam
S
Thomson Scientific, London, UK. sam.enefer@thomson.com
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology; D017321:Clinical Trials, Phase I as Topic; D003424:Crohn Disease / Q000188:drug therapy; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004195:Disease Models, Animal; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use; D000882:Haplorhini; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use; D016173:Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy; D016328:NF-kappa B / Q000627:therapeutic use; D000069442:Natalizumab; D009930:Organic Chemicals / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015507:Drugs, Investigational; D007074:Immunoglobulin G; D007211:Indoles; D007375:Interleukin-1; D016328:NF-kappa B; D000069442:Natalizumab; D009930:Organic Chemicals; C456900:indolin-2-one; C506613:oglemilast; D016173:Macrophage Colony-Stimulating Factor; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4